Arrowhead Pharmaceuticals, Inc. ARWR
48.88 USD -9.28 (-15.96%)
Nov 9, 2026, 3:17 PM EST
46.45 Day range 53.63
38.09 52-week range 89.59
- YTD
- -26.37%
- 1 year
- +24.60%
News
benzinga.com Nasdaq 100 Jumps 3% as Chips Rebound; Nvidia Lags Most Since DeepSeek: Stock Market Today Wall Street rebounds from last week's rout as SOXX jumps 7%, while Nvidia slides on a CEO probe for its worst day versus the S&P 500 since DeepSeek.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
benzinga.com Reported Saturday, Arrowhead Presents Plozasiran Data At AHA 2026 Showing 78% Lower Acute Pancreatitis Event Rate Versus Placebo And Sustained Triglyceride Reductions, Plus ARO-DIMER-PA Lowering LDL Cholesterol And Triglycerides Pooled SHASTA-3 and SHASTA-4 analysis showed plozasiran reduced acute pancreatitis event rates by 78% overall and 91% in sHTG patients with a recent history of acute pancreatitis versus…
businesswire.com Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the…
benzinga.com Arrowhead Refinances Debt, Cuts Borrowing Costs And Boosts Financial Flexibility With New $400M Sixth Street Loan - Existing $400 million facility prepaid at a $68 million discount to the contractual minimum repayment amount- New $400 million term loan priced at SOFR plus 5.50%- Debt has no scheduled…
businesswire.com Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing…
benzinga.com Arrowhead Pharma To Present Three-Year Data From PALISADE Study And Open-Label Extension At American Heart Association Scientific Sessions 2026 – Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking…
businesswire.com Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026 PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week's American Heart Association Scientific Sessions in…
benzinga.com Arrowhead Pharmaceuticals’ REDEMPLO Receives UK Marketing Authorization For Familial Chylomicronaemia Syndrome; NICE Recommends NHS Funding In England And Wales For Eligible Adults With Genetically Confirmed FCS The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients…
benzinga.com Top 3 Health Care Stocks That Could Blast Off In October Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
benzinga.com HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.
benzinga.com Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results Arrowhead Pharma shares Phase 1/2a data for ARO-MAPT, showing up to 85% tau reduction in central nervous system Alzheimer's disease trial.- benzinga.com Arrowhead Reports First Clinical Validation Of TRiM Platform As ARO-MAPT Achieves Up To 73% Mean and 85% Maximum Tau Reduction Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau…
- benzinga.com Arrowhead Announces Interim Results From Ongoing Phase 1/2a Study Of ARO-MAPT, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Alzheimer’s Disease And Other Tauopathies Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau…
- benzinga.com Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.
benzinga.com Nasdaq 100 Slips, 10-Year Yields Hit 19-Year Highs: Stock Market Today Stocks slid as the 10-year Treasury yield hit a 19-year high on blowout PMI data; cybersecurity stocks bucked the selloff.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Arrowhead Achieves Clinical Validation for New Drug Platform Arrowhead Pharmaceuticals reports interim Phase 1/2a data for ARO-DIMER-PA, demonstrating dual-gene silencing to treat high fat in blood.
benzinga.com 10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.- benzinga.com Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108 Citigroup analyst Eric Joseph initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $108.
benzinga.com HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.- benzinga.com RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.
- benzinga.com Reported Earlier, Arrowhead Reports Plozasiran Also Reduced Pancreatitis Risk In Severe Triglyceride Patients Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a…
- benzinga.com Arrowhead Pharmaceuticals To Present Data On Plozasiran In Patients With Severe Hypertriglyceridemia At European Society Of Cardiology Congress Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich, Germany.
- benzinga.com Arrowhead Pharma’s REDEMPLO Authorized In EU; Now Prescribable And Reimbursable In Germany For Familial Chylomicronaemia Syndrome REDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either…
benzinga.com HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120 HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $115 to $120.- benzinga.com Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.32) by 3.03 percent. This is a 7.94 percent decrease over losses of…
benzinga.com Arrowhead Pharmaceuticals Enters Agreement With Undisclosed Third Party To Acquire An FDA Rare Pediatric Disease Priority Review Voucher For Its Upcoming SNDA Submission For Plozasiran, Anticipated Before The End Of 2026 SNDA to seek approval to expand the approved indication to include patients with severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis,…- benzinga.com B. Riley Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $123 B. Riley Securities analyst Madison El-Saadi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $101 to $123.
benzinga.com 4 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Ford To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Monday Wall Street analysts changed outlook on top names. See all rating changes on Benzinga's analyst ratings page for F, RIVN, TSM, ZVRA, ARWR, VZ, HBAN, GM, SAP, and CHTR.- benzinga.com Arrowhead Pharmaceuticals Completes Patient Enrollment In Its Global Phase 3 YOSEMITE Clinical Study Of Zodasiran To Treat Homozygous Familial Hypercholesterolemia Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company’s investigational RNA…
benzinga.com HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $115 HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $100 to $115.- benzinga.com Morgan Stanley Maintains Overweight on Arrowhead Pharma, Raises Price Target to $120 Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $100 to $120.
- benzinga.com Piper Sandler Reiterates Overweight on Arrowhead Pharma, Raises Price Target to $126 Piper Sandler analyst Edward Tenthoff reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $110 to $126.
- benzinga.com Chardan Capital Maintains Buy on Arrowhead Pharma, Raises Price Target to $115 Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $90 to $115.
benzinga.com Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreatitis reductions.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday's regular session. The company's market cap stands at $11.5 million. Lakewood-Amedex (NASDAQ:LABT)…
benzinga.com Stock Market Today: Nasdaq 100 Falls as Crude Rallies to $88 Stocks split as oil climbs on the 11th night of Iran strikes and Super Micro rockets 26% on a record backlog, while the Nasdaq slips ahead of Alphabet, Tesla.
benzinga.com Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 Earnings U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 200 points on Wednesday. The Dow traded up 0.40% to 52,432.64 while the NASDAQ declined 0.01% to…
benzinga.com CME Group, Weatherford International, RPM International And Other Big Stocks Moving Higher On Wednesday Dow Jones up 200 pts, CME Group shares rise on upbeat earnings. Super Micro Computer, Arrowhead Pharma, Phoenix Asia, Everforth also gain.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers InMed Pharmaceuticals (NASDAQ:INM) stock moved upwards by 66.8% to $2.57 during Wednesday's pre-market session. The company's market cap stands at $8.2 million. China SXT Pharmaceuticals…- benzinga.com Arrowhead Pharmaceuticals Announces Topline Results For Phase 3 SHASTA-3 And SHASTA-4 Clinical Studies Of Plozasiran In Patients With Severe Hypertriglyceridemia; Observes Deep, Durable, And Consistent Median Triglyceride Reductions Of 79% And 81% From Baseline Statistically significant reduction in acute pancreatitis events versus placebo across the entire sHTG study population, with an unprecedented 100% event reduction in high-risk patientsContinued and…
- benzinga.com JP Morgan Maintains Overweight on Arrowhead Pharma, Raises Price Target to $95 JP Morgan analyst Brian Cheng maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $88 to $95.
benzinga.com This Arrowhead Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts changed outlook on top names, including RXO, AMBQ, BE, ARWR, FSLR. See ratings page for upgrades, downgrades, and initiations.- benzinga.com Stifel Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $98 Stifel analyst James Condulis initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $98.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $100 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $100 price target.
benzinga.com Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.- benzinga.com Arrowhead Pharmaceuticals Receives European Commission Marketing Authorization For REDEMPLO To Lower Triglyceride Levels In Adult Patients With Familial Chylomicronemia Syndrome Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for REDEMPLO® (plozasiran), a small interfering RNA…
benzinga.com Leerink Partners Maintains Market Perform on Arrowhead Pharma, Raises Price Target to $72 Leerink Partners analyst Mani Foroohar maintains Arrowhead Pharma (NASDAQ:ARWR) with a Market Perform and raises the price target from $61 to $72.